文献速递免疫规划传染病防控与疫情报告

蓝舌病禁用感染性单动物(DISA)疫苗:绵羊最佳接种途径与剂量的研究

Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep.
PubMed 文献 · Vaccine · 2016-12-01

蓝舌病由库蠓传播的蓝舌病毒引起,现有疫苗有缺陷。研究基于不表达NS3/NS3a蛋白的减毒蓝舌病毒DISA疫苗,在绵羊中测试不同剂量与接种途径。结果显示剂量稀释10倍和100倍不降低VP7体液应答,肌内接种诱导的VP7血清转阳强于皮下,肌内接种为最佳途径。

要点

  • DISA疫苗剂量稀释10倍和100倍不降低VP7体液应答。
  • 肌内接种诱导的VP7血清转阳强于皮下接种。
  • 肌内接种为最佳接种途径。

核心结论

  • 肌内接种是DISA疫苗的最佳接种途径。
  • DISA疫苗的保护剂量尚未确定,但预计显著低于目前使用的蓝舌病疫苗。

研究设计与样本

  • 研究在绵羊中测试DISA疫苗的接种途径与剂量。
  • 使用标准化剂量的血清型8 DISA疫苗,此前已通过皮下接种测试。
  • 测试了该剂量稀释10倍和100倍的效果。
  • 比较了静脉、肌内和皮下接种途径。
  • 使用了两种不同的DISA疫苗骨架。

主要发现

  • 剂量稀释10倍和100倍不降低VP7体液应答。
  • 静脉接种诱导高且持久的体液应答,但在现场条件下不实用。
  • 肌内接种的VP7血清转阳强于皮下接种。
  • 两种接种途径和两种DISA疫苗骨架中,IgM抗体快速诱导但在接种后14天下降,而IgG应答较慢。
  • 肌内接种导致初始峰值后下降至接种后21天,然后IgG抗体再次稳定持续增加。

临床怎么用

  • 作者认为肌内接种是DISA疫苗的最佳接种途径。
  • DISA疫苗的保护剂量尚未确定,但预计显著低于目前使用的蓝舌病疫苗。

局限性

  • DISA疫苗的保护剂量尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bluetongue (BT) is a disease of ruminants caused by bluetongue virus (BTV) transmitted by biting midges of the Culicoides genus. Outbreaks have been controlled successfully by vaccination, however, currently available BT vaccines have several shortcomings. Recently, we have developed BT Disabled Infectious Single Animal (DISA) vaccines based on live-attenuated BTV without expression of dispensable non-structural NS3/NS3a protein. DISA vaccines are non-pathogenic replicating vaccines, do not cause viremia, enable DIVA and are highly protective. NS3/NS3a protein is involved in virus release, cytopathogenic effect and suppression of Interferon-I induction, suggesting that the vaccination route can be of importance. A standardized dose of DISA vaccine for serotype 8 has successfully been tested by subcutaneous vaccination. We show that 10 and 100times dilutions of this previously tested dose did not reduce the VP7 humoral response. Further, the vaccination route of DISA vaccine strongly determined the induction of VP7 directed antibodies (Abs). Intravenous vaccination induced high and prolonged humoral response but is not practical in field situations. VP7 seroconversion was stronger by intramuscular vaccination than by subcutaneous vaccination. For both vaccination routes and for two different DISA vaccine backbones, IgM Abs were rapidly induced but declined after 14days post vaccination (dpv), whereas the IgG response was slower. Interestingly, intramuscular vaccination resulted in an initial peak followed by a decline up to 21dpv and then increased again. This second increase is a steady and continuous increase of IgG Abs. These results indicate that intramuscular vaccination is the optimal route. The protective dose of DISA vaccine has not been determined yet, but it is expected to be significantly lower than of currently used BT vaccines. Therefore, in addition to the advantages of improved safety and DIVA compatibility, the novel DISA vaccines will be cost-competitive to commercially available live attenuated and inactivated vaccines for Bluetongue.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Rijn PA, Daus FJ, Maris-Veldhuis MA, et al. Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep. Vaccine. 2016. PMID: 27916409. doi:10.1016/j.vaccine.2016.11.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。